# Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.

> **NCT00645502** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 40 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorders

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00645502
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645502, "Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00645502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*